Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 459

1.

Chronic toxicity of inhaled thymol in lungs and respiratory tracts in mouse model.

Xie K, Tashkin DP, Luo MZ, Zhang JY.

Pharmacol Res Perspect. 2019 Aug 27;7(5):e00516. doi: 10.1002/prp2.516. eCollection 2019 Oct.

2.

Pharmacokinetic study of thymol after intravenous injection and high-dose inhalation in mouse model.

Xie K, Tashkin DP, Luo MZ, Zhang JY.

Pharmacol Res Perspect. 2019 Aug 19;7(5):e00515. doi: 10.1002/prp2.515. eCollection 2019 Oct.

3.

Spirometric indices of early airflow impairment in individuals at risk of developing COPD: Spirometry beyond FEV1/FVC.

Hoesterey D, Das N, Janssens W, Buhr RG, Martinez FJ, Cooper CB, Tashkin DP, Barjaktarevic I.

Respir Med. 2019 Sep;156:58-68. doi: 10.1016/j.rmed.2019.08.004. Epub 2019 Aug 9. Review.

PMID:
31437649
4.

Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease.

Kim GHJ, Tashkin DP, Lo P, Brown MS, Volkmann ER, Gjertson DW, Khanna D, Elashoff RM, Tseng CH, Roth MD, Goldin JG.

Arthritis Rheumatol. 2019 Aug 20. doi: 10.1002/art.41085. [Epub ahead of print]

PMID:
31430058
5.

Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies.

Tashkin DP, Goodin T, Bowling A, Price B, Ozol-Godfrey A, Sharma S, Sanjar S.

Respir Med. 2019 Aug;155:113-120. doi: 10.1016/j.rmed.2019.07.019. Epub 2019 Jul 19.

PMID:
31344660
6.

Pulmonary effects of inhaled cannabis smoke.

Tashkin DP, Roth MD.

Am J Drug Alcohol Abuse. 2019 Jul 12:1-14. doi: 10.1080/00952990.2019.1627366. [Epub ahead of print]

PMID:
31298945
7.

Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies.

Tashkin DP, Goodin T, Bowling A, Price B, Ozol-Godfrey A, Sharma S, Sanjar S.

Respir Res. 2019 Jul 2;20(1):135. doi: 10.1186/s12931-019-1112-0.

8.

Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis.

Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S.

Arthritis Rheumatol. 2019 Jun 24. doi: 10.1002/art.41020. [Epub ahead of print]

PMID:
31233287
9.

Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.

Volkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, Clements PJ, Hoffmann-Vold AM, Furst DE, Kim G, Goldin J, Elashoff RM.

J Rheumatol. 2019 Feb 15. pii: jrheum.180441. doi: 10.3899/jrheum.180441. [Epub ahead of print]

PMID:
30770517
10.

Heroin Smoking and COPD: A Case for Targeted Screening Spirometry.

Tashkin DP.

Chest. 2019 Feb;155(2):247-248. doi: 10.1016/j.chest.2018.08.1039. No abstract available.

PMID:
30732683
11.

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Khanna D, Clements PJ, Volkmann ER, Wilhalme H, Tseng CH, Furst DE, Roth MD, Distler O, Tashkin DP.

Arthritis Res Ther. 2019 Jan 16;21(1):23. doi: 10.1186/s13075-019-1809-y.

12.

Heterogeneous burden of lung disease in smokers with borderline airflow obstruction.

Pirozzi CS, Gu T, Quibrera PM, Carretta EE, Han MK, Murray S, Cooper CB, Tashkin DP, Kleerup EC, Barjaktarevic I, Hoffman EA, Martinez CH, Christenson SA, Hansel NN, Graham Barr R, Bleecker ER, Ortega VE, Martinez FJ, Kanner RE, Paine R 3rd; NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS).

Respir Res. 2018 Nov 20;19(1):223. doi: 10.1186/s12931-018-0911-z.

13.

Controversies in Allergy: Is Asthma Chronic Obstructive Pulmonary Disease Overlap a Distinct Syndrome That Changes Treatment and Patient Outcomes?

Tashkin DP, Peebles RS Jr.

J Allergy Clin Immunol Pract. 2019 Apr;7(4):1142-1147. doi: 10.1016/j.jaip.2018.10.024. Epub 2018 Nov 14. Review. No abstract available.

PMID:
30448110
14.

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, Elashoff RM, Sullivan KM; SLS I and SLS II study groups.

Ann Rheum Dis. 2019 Jan;78(1):122-130. doi: 10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8.

15.

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.

Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A.

Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.

16.

Vaping Cannabis and Chronic Obstructive Pulmonary Disease.

Tashkin DP.

Ann Am Thorac Soc. 2018 Oct;15(10):1137-1138. doi: 10.1513/AnnalsATS.201807-463ED. No abstract available.

PMID:
30272498
17.

Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.

Goldin JG, Kim GHJ, Tseng CH, Volkmann E, Furst D, Clements P, Brown M, Roth M, Khanna D, Tashkin DP.

Ann Am Thorac Soc. 2018 Nov;15(11):1286-1295. doi: 10.1513/AnnalsATS.201802-079OC.

PMID:
30265153
18.

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?

Tashkin DP, Strange C.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 27;13:2587-2601. doi: 10.2147/COPD.S172240. eCollection 2018. Review.

19.

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.

Tashkin DP, Gross NJ.

Int J Chron Obstruct Pulmon Dis. 2018 Jun 12;13:1873-1888. doi: 10.2147/COPD.S162646. eCollection 2018. Review.

20.

To Withdraw or Not to Withdraw Inhaled Corticosteroids from Triple Therapy in Chronic Obstructive Pulmonary Disease.

Tashkin DP.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):292-294. doi: 10.1164/rccm.201805-0979ED. No abstract available.

PMID:
29916719
21.

Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S.

Rheumatology (Oxford). 2019 Apr 1;58(4):567-579. doi: 10.1093/rheumatology/key151.

22.

Marijuana and Lung Disease.

Tashkin DP.

Chest. 2018 Sep;154(3):653-663. doi: 10.1016/j.chest.2018.05.005. Epub 2018 May 17. Review.

PMID:
29778658
23.

Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).

Morris MA, Jacobson SR, Kinney GL, Tashkin DP, Woodruff PG, Hoffman EA, Kanner RE, Cooper CB, Drummond MB, Barr RG, Oelsner EC, Make BJ, Han MK, Hansel NN, O'Neal WK, Bowler RP.

Chronic Obstr Pulm Dis. 2018 Jan 24;5(1):46-56. doi: 10.15326/jcopdf.5.1.2017.0141.

24.

Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease.

Tashkin DP, Wechsler ME.

Int J Chron Obstruct Pulmon Dis. 2018 Jan 17;13:335-349. doi: 10.2147/COPD.S152291. eCollection 2018. Review.

25.

A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers.

Kiertscher SM, Gangalum PR, Ibrahim G, Tashkin DP, Roth MD.

J Neuroimmune Pharmacol. 2018 Jun;13(2):219-229. doi: 10.1007/s11481-018-9776-7. Epub 2018 Jan 16.

26.

Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years.

Bhatt SP, Kim YI, Harrington KF, Hokanson JE, Lutz SM, Cho MH, DeMeo DL, Wells JM, Make BJ, Rennard SI, Washko GR, Foreman MG, Tashkin DP, Wise RA, Dransfield MT, Bailey WC; COPDGene Investigators.

Thorax. 2018 May;73(5):414-421. doi: 10.1136/thoraxjnl-2017-210722. Epub 2018 Jan 11.

27.

Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.

Ferguson GT, Tashkin DP, Skärby T, Jorup C, Sandin K, Greenwood M, Pemberton K, Trudo F.

Respir Med. 2017 Nov;132:31-41. doi: 10.1016/j.rmed.2017.09.002. Epub 2017 Sep 5.

28.

Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):644-652. doi: 10.1164/rccm.201709-1845OC. Epub 2017 Nov 3.

29.

Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, Wells A.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203. Review.

30.

Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Wise RA, Acevedo RA, Anzueto AR, Hanania NA, Martinez FJ, Ohar JA, Tashkin DP.

Chronic Obstr Pulm Dis. 2016 Nov 15;4(1):7-20. doi: 10.15326/jcopdf.4.1.2016.0141.

31.

Triple Therapy for Chronic Obstructive Pulmonary Disease Management. Are Our Expectations Fulfilled?

Tashkin DP, Taube C.

Am J Respir Crit Care Med. 2017 Aug 15;196(4):402-404. doi: 10.1164/rccm.201704-0760ED. No abstract available.

PMID:
28809512
32.

Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24].

Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C.

Respir Med. 2017 Aug;129:164. doi: 10.1016/j.rmed.2017.06.011. Epub 2017 Jun 30. No abstract available.

33.

Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.

Han MK, Quibrera PM, Carretta EE, Barr RG, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL, Criner G, Dransfield MT, Hansel NN, Hoffman EA, Kanner RE, Krishnan JA, Martinez CH, Pirozzi CB, O'Neal WK, Rennard S, Tashkin DP, Wedzicha JA, Woodruff P, Paine R 3rd, Martinez FJ; SPIROMICS investigators.

Lancet Respir Med. 2017 Aug;5(8):619-626. doi: 10.1016/S2213-2600(17)30207-2. Epub 2017 Jun 28.

34.

Effect of a single exacerbation on decline in lung function in COPD.

Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP.

Respir Med. 2017 Jul;128:85-91. doi: 10.1016/j.rmed.2017.04.013. Epub 2017 Apr 24.

35.

Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.

Namas R, Tashkin DP, Furst DE, Wilhalme H, Tseng CH, Roth MD, Kafaja S, Volkmann E, Clements PJ, Khanna D; Participants in the Scleroderma Lung Study I and members of the Scleroderma Lung Study II Research Group.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):439-444. doi: 10.1002/acr.23282. Epub 2018 Feb 9.

36.

Respiratory Symptoms Items from the COPD Assessment Test Identify Ever-Smokers with Preserved Lung Function at Higher Risk for Poor Respiratory Outcomes. An Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort.

Martinez CH, Murray S, Barr RG, Bleecker E, Bowler RP, Christenson SA, Comellas AP, Cooper CB, Couper D, Criner GJ, Curtis JL, Dransfield MT, Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Krishnan JA, Lazarus SC, Leidy NK, O'Neal W, Martinez FJ, Paine R 3rd, Rennard SI, Tashkin DP, Woodruff PG, Han MK; Subpopulations and Intermediate Outcome Measures in COPD Study Investigators.

Ann Am Thorac Soc. 2017 May;14(5):636-642. doi: 10.1513/AnnalsATS.201610-815OC.

37.

Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.

Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, Quinn D, Siddiqui S, Orevillo C, Maes A, Reisner C.

Respir Med. 2017 May;126:105-115. doi: 10.1016/j.rmed.2017.03.015. Epub 2017 Mar 12.

38.

Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.

Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM.

Arthritis Rheumatol. 2017 Jul;69(7):1451-1460. doi: 10.1002/art.40114. Epub 2017 May 23.

39.

Asthma-chronic obstructive pulmonary disease overlap syndrome: What we know and what we need to find out.

Desai M, Oppenheimer J, Tashkin DP.

Ann Allergy Asthma Immunol. 2017 Mar;118(3):241-245. doi: 10.1016/j.anai.2016.12.016. No abstract available.

PMID:
28284529
40.

Case-control study of cumulative cigarette tar exposure and lung and upper aerodigestive tract cancers.

Meyers TJ, Chang SC, Chang PY, Morgenstern H, Tashkin DP, Rao JY, Cozen W, Mack TM, Zhang ZF.

Int J Cancer. 2017 May 1;140(9):2040-2050. doi: 10.1002/ijc.30632. Epub 2017 Feb 22.

41.

Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.

Volkmann ER, Tashkin DP, Roth MD, Clements PJ, Khanna D, Furst DE, Mayes M, Charles J, Tseng CH, Elashoff RM, Assassi S.

Arthritis Res Ther. 2016 Dec 30;18(1):305. doi: 10.1186/s13075-016-1203-y.

42.

Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.

Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, Clements PJ, Theodore A, Kafaja S, Kim GH, Goldin J, Ariolla E, Elashoff RM.

Chest. 2017 Apr;151(4):813-820. doi: 10.1016/j.chest.2016.11.052. Epub 2016 Dec 22.

43.

Evaluating small-airways disease in asthmatic patients: The utility of quantitative computed tomography.

Tashkin DP, Kim HJ, Zeidler M, Kleerup E, Goldin J.

J Allergy Clin Immunol. 2017 Jan;139(1):49-51.e2. doi: 10.1016/j.jaci.2016.11.010. Epub 2016 Nov 21. No abstract available.

PMID:
27884601
44.

Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses.

Tashkin DP, Bateman ED, Jones P, Zubek VB, Metzdorf N, Liu D, Leonard T, Clerisme-Beaty E, Wise RA.

Respir Med. 2016 Nov;120:91-100. doi: 10.1016/j.rmed.2016.10.002. Epub 2016 Oct 11.

45.

A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.

Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C.

Respir Med. 2016 Nov;120:16-24. doi: 10.1016/j.rmed.2016.09.012. Epub 2016 Sep 17. Erratum in: Respir Med. 2017 Aug;129:164.

46.

A review of nebulized drug delivery in COPD.

Tashkin DP.

Int J Chron Obstruct Pulmon Dis. 2016 Oct 18;11:2585-2596. eCollection 2016. Review.

47.
48.

Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.

Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, Dahl R, Paggiaro P, Vandewalker M, Schmidt H, Engel M, Bateman ED.

Respir Med. 2016 Aug;117:198-206. doi: 10.1016/j.rmed.2016.06.013. Epub 2016 Jun 14.

49.

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM; Sclerodema Lung Study II Investigators.

Lancet Respir Med. 2016 Sep;4(9):708-719. doi: 10.1016/S2213-2600(16)30152-7. Epub 2016 Jul 25.

50.

Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function.

Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE, Kleerup E, Lazarus SC, Martinez FJ, Paine R 3rd, Rennard S, Tashkin DP, Han MK; SPIROMICS Research Group.

N Engl J Med. 2016 May 12;374(19):1811-21. doi: 10.1056/NEJMoa1505971.

Supplemental Content

Loading ...
Support Center